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ABSTRACT
Introduction More than 90% of patients diagnosed with 
childhood acute lymphoblastic leukaemia (ALL) today 
will survive. However, half of the survivors are expected 
to experience therapy- related chronic or late occurring 
adverse effects, reducing quality of life. Insight into 
underlying risk trajectories is warranted. The aim of this 
study is to establish a Nordic, national childhood ALL 
survivor cohort, to be investigated for the total somatic 
and psychosocial treatment- related burden as well as 
associated risk factors, allowing subsequent linkage to 
nation- wide public health registers.
Methods and analysis This population- based 
observational cohort study includes clinical follow- up of 
a retrospective childhood ALL survivor cohort (n=475), 
treated according to a common Nordic ALL protocol during 
2008–2018 in Denmark. The study includes matched 
controls. Primary endpoints are the cumulative incidence 
and cumulative burden of 197 health conditions, assessed 
through self- report and proxy- report questionnaires, 
medical chart validation, and clinical examinations. 
Secondary endpoints include organ- specific outcome, 
including cardiovascular and pulmonary function, physical 
performance, neuropathy, metabolic disturbances, hepatic 
and pancreatic function, bone health, oral and dental 
health, kidney function, puberty and fertility, fatigue, and 
psychosocial outcome. Therapy exposure, acute toxicities, 
and host genome variants are explored as risk factors.
Ethics and dissemination The study is approved by 
the Regional Ethics Committee for the Capital Region in 
Denmark (H-18035090/H-20006359) and by the Danish 
Data Protection Agency (VD-2018–519). Results will be 
published in peer- reviewed journals and are expected 
to guide interventions that will ameliorate the burden of 
therapy without compromising the chance of cure.
INTRODUCTION
Five- year overall survival rates for childhood 
acute lymphoblastic leukaemia (ALL) has 
climbed from less than 10% to above 90% 
during the last seven decades as a result 
of chemotherapy intensification, refined 
risk stratification and improved supportive 
care.1–3 However, cure comes at a cost.4 All 
patients experience acute, but transient toxic-
ities during therapy (eg, infections, mucositis 
and peripheral neuropathy), and half of the 
patients are burdened by at least one severe, 
potentially life- threatening organ toxicity, 
such as acute pancreatitis, thromboembo-
lism, or severe neurotoxicity.5–8 Acute organ 
damage resulting from leukaemia and/or 
therapy may persist (eg, insulin- dependent 
Strengths and limitations of this study
 ► The first population- based, uniformly treated, Nordic 
childhood and young adult acute lymphoblastic leu-
kaemia (ALL) survivor cohort to be systematically 
evaluated for treatment- related organ- wide morbid-
ity and psychosocial impact.
 ► Additional strengths include use of matched con-
trols, systematic subjective and objective assess-
ments of outcome and alignment of adverse effects 
definitions with established classification systems.
 ► Estimation of the cumulative burden includes both 
persistent and recurrent events, thereby describing 
the total disease burden more comprehensively than 
traditional measures, such as cumulative incidence.
 ► Initial cross- sectional analyses are limited by a 
follow- up of 3.5–14 years, acknowledging that the 
full burden of ALL and leukaemic therapy may not 
yet have emerged.
 ► Self- report and systematic clinical data will supple-
ment data from the Danish nationwide public demo-
graphic, socioeconomic and health registries.  on M
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diabetes)9 or emerge (eg, osteonecrosis)10 several years 
into survival as late effects. The 30- year- old survivor will 
have experienced an average of 5.4 health conditions, 
and half of survivors face at least one chronic health 
condition 20 years from ALL diagnosis, both measures 
significantly exceeding those among siblings and commu-
nity controls.11 12 This disproportion in morbidity rate 
seems to amplify with increasing age.12 Certain ther-
apeutic exposures have been reduced over time (eg, 
reduction in cardiotoxic anthracycline exposure and 
limited use of cranial irradiation in first- line therapy 
protocols),13 14 which has decreased the risk of early 
mortality and lowered the prevalence of treatment- related 
cancers, severe cognitive deficits, hypothalamic- pituitary 
dysfunction and immunological disease.12 14 However, the 
number of health conditions per individual survivor is 
still double of that in controls, now dominated by endo-
crine system disorders, and musculoskeletal, neurolog-
ical and cardiovascular conditions,12 maintaining risk of 
impaired physical, cognitive and emotional functions, 
socioeconomic achievements and health- related quality 
of life.11 15–18 Therapy exposure and genetic susceptibility 
are considered the two major risk factors predicting late 
morbidity.19 Risk of specific late effects are associated 
with cumulative chemotherapy exposures,20–29 but no 
safe lower doses have been established. Specific genetic 
variants have been linked with survivor obesity, reduced 
bone mineral density (BMD), cardiotoxicity, skeletal 
muscle dysfunction and neurocognitive dysfunction;30–33 
however, clinical recommendations await harmonisation 
of outcomes, larger sample sizes and replication in inde-
pendent cohorts.30
To date, many late effects studies are observational 
and focus on one or few organ systems, cross- sectional 
in design, or emerge from single centres with resulting 
risk of selection bias and limited sample power. A few 
very large (>10 000 patients), multi- institutional child-
hood cancer survivor cohort studies exist, such as the 
US Childhood Cancer Survivor Study,34 the Nordic 
Adult Life after Childhood Cancer in Scandinavia 
study35 and the British Childhood Cancer Survivor 
Study.36 Most studies emerging from these cohorts 
rely on self- reported and register- based data, while few 
collect systematic clinical data, none of which include 
Nordic survivors.37
During the 10- year period of 2008–2018, patients diag-
nosed with Philadelphia chromosome- negative (Ph−) 
ALL at age 1–45 years in the Nordic and Baltic coun-
tries, have been treated according to the Nordic Society 
of Paediatric Haematology and Oncology (NOPHO) 
ALL2008 protocol described elsewhere.3 5 38 Two thirds 
of this cohort were below 18 years of age at diagnosis. 
The aim of the Acute Lymphoblastic Leukemia Survivor 
Toxicity And Rehabilitation (ALL- STAR) study is to 
establish a national, Danish NOPHO ALL2008 survivor 
cohort, to be assessed for the total somatic and psychoso-
cial treatment- related burden, using both self- report and 
systematic clinical data that will supplement data from the 





To quantify the burden of health conditions occurring 
during the first decade of survivorship among survivors of 
childhood and young adult ALL.
Secondary aims
To describe, in detail, organ- specific health among survi-
vors as compared with matched controls and normative 
data; and to investigate host genome variants, therapy 
exposure and acute toxicities as risk factors for organ- 
specific late effects and for the overall cumulative 
burden. Furthermore, to establish a platform for life- long 
follow- up in this survivor cohort, facilitating longitudinal 
studies and linkage to nationwide public, socioeconomic 
and health registries.
Study design
The ALL- STAR study is a national, Danish, population- 
based, observational cohort study, including prospec-
tive clinical follow- up in a retrospective childhood and 
young adult ALL survivor cohort. This present protocol 




Survivors treated in Denmark according to the NOPHO 
ALL2008 protocol and minimum 1 year from therapy 
cessation (3.5 years from ALL diagnosis) are eligible. 
This corresponds to all patients (n=475) aged 1–45 years 
at diagnosis with Ph− B- cell precursor or T- cell ALL, diag-
nosed between July 2008 and October 2018 (the complete 
NOPHO ALL2008 protocol period). A control group 
consisting of age- and sex- matched individuals (1:1) is 
recruited for the study. First- degree relatives to survivors 
and individuals with previous or ongoing cancer, previous 
or ongoing chemotherapy, and/or previous or ongoing 
radiation therapy are excluded as controls. Study recruit-
ment for the initial cross- sectional studies opened in 
February 2019 and will terminate in September 2022, 
allowing for the entire survivor cohort to meet the inclu-
sion criteria.
Recruitment
Eligible survivors are identified through the NOPHO 
ALL2008 registry. Contact information is obtained 
through medical charts and provided by treating physi-
cians to the research team. Written information is sent to 
parents if survivor’s age is <15 (addressed to survivor and 
parents), to parents and the survivor if aged 15–17.9, and 
to survivors if aged ≥18 years. Contact is obtained through 
subsequent phone calls. All survivors and/or families are 
invited to an on- site meeting for further information 
 on M
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before consent. Controls are recruited via participating 
survivors (or parents) who appoint and invite friends or 
relatives to participate. Potential controls (or parents) 
contact the research team, with subsequent written and 
oral information provided as described for survivors, 
before possible consent.
Endpoints
Primary endpoints and hypothesis
The two primary endpoints are cumulative incidence and 
cumulative burden of 197 health conditions presented in 
table 1.
We hypothesise that the cumulative incidence and 
cumulative burden are significantly higher among survi-
vors of childhood and young adult ALL already during 
the first decade of survival, when compared with age- and 
sex- matched controls, and normative data.
The measure of cumulative burden considers occur-
rence of multiple health conditions and recurrent events, 
thereby encompassing the total disease burden more 
comprehensively than cumulative incidence, which 
includes only first occurrence of an event.40 41 The 197 
conditions investigated in the ALL- STAR study are 
defined and graded according to the St Jude Children’s 
Research Hospital modification of the National Cancer 
Institute’s Common Terminology Criteria for Adverse 
Events (CTCAE; V.4.03),42 developed to optimise charac-
terisation of long- term and late- onset health conditions 
among childhood cancer survivors.43 Ten additional 
health conditions (generalised muscle weakness, reduced 
cardiopulmonary fitness, sarcopenic obesity and seven 
oral/dental conditions) have been added. Definitions 
and grading criteria for all conditions are provided in 
online supplemental table 1.
Secondary endpoints
Secondary endpoints include: (1) organ- specific outcome, 
including metabolic syndrome (MetS) and body composi-
tion, hepatic function, pancreatic function, bone health, 
cardiac function, pulmonary function, peripheral and 
autonomic neuropathy, physical performance, renal func-
tion, pubertal timing, fertility, oral and dental health, and 
(2) psychosocial outcome, including emotional distress, 
fatigue and health- related quality of life.
An overview of the ALL- STAR study is provided in 
figure 1.
Data collection
Data are collected through questionnaires and clinical 
evaluations. An overview of ALL- STAR source data used 
for evaluation of the 197 health conditions is provided in 
online supplemental table 1.
Questionnaire data
An electronic questionnaire is sent to participants prior 
to clinical examinations. The questionnaire is adjusted 
according to self- report (age ≥15 years), proxy report 
(age <18), age, sex, and status as survivor or control. 
Items include demographics, use of healthcare services, 
medicine and nutritional supplements, medical history 
(including age at diagnosis of a confirmed condition), 
pubertal status and fertility, familial dispositions, health 
behaviour, mental health, quality of life and socioeco-
nomic status. An overview of questionnaire versions and 
content is provided in online supplemental table 2.
Clinical data
All clinical examinations are performed at either Copen-
hagen University Hospital or Aarhus University Hospital, 
as requested by the participant. Examinations are 
performed during 10 hours in a single day. The examina-
tion programme and description of clinical investigators 
are provided in online supplemental table 3.
Evaluation of metabolic syndrome and body composition
Endpoints include MetS, insulin sensitivity, lipid profile, 
abdominal circumference, body mass index (BMI) for 
adults and BMI standard deviation (SD) scores for chil-
dren based on national reference material,44 45 lean body 
mass, and fat mass. Adult MetS is defined according to 
the National Cholesterol Education Program Adult 
Treatment Panel criteria,46 and includes central obesity, 
dyslipidaemia, hypertension and elevated fasting glucose. 
Paediatric MetS is defined using the same measures.47 
Questionnaire items include metabolic disease and 
family disposition, prescription medicine, nutritional 
supplements and lifestyle (diet, level of physical activity, 
and sedentary behaviour). Clinical investigations include 
anthropometrics (weight, height and abdominal circum-
ference) and blood pressure (described in cardiovascular 
section). Fasting blood samples include glucose, glycated 
haemoglobin, insulin, proinsulin c- peptide, total choles-
terol, high- density lipoprotein cholesterol, low- density 
lipoprotein cholesterol, very low- density lipoprotein 
cholesterol, triglycerides, glucagon and leptin. Homeo-
static Model Assessment for Insulin resistance score is 
calculated as fasting plasma glucose (mmol/L)×fasting 
plasma insulin (μU/L)/22.5.48 Body composition (fat 
and lean body mass, and android/gynoid fat distribu-
tion) is assessed with dual- energy X- ray absorptiometry 
(DXA) (Lunar Prodigy, GE Healthcare, Wisconsin, USA; 
or Hologic Horizon A, Hologic, Marlborough, Massachu-
setts, USA), and is adjusted for sex and pubertal stage.
Evaluation of hepatic function and gallbladder
Endpoints include signs of hepatocellular damage, 
impaired liver synthesis, iron overload, hepatic fibrosis, 
portal hypertension and gall bladder disease (cholestasis, 
cholangitis and cholelithiasis). Questionnaire items 
include symptoms of hepatic disease (fatigue, abdom-
inal pain, nausea, jaundice, discoloured urine and itchy 
skin), hepatic diagnoses, alcohol consumption and use 
of prescription medicine. Fasting blood samples include 
alanine transaminase, aspartate transaminase, alkaline 
phosphatase, gamma- glutamyl transferase, bilirubin, 
lactate dehydrogenase, prothrombin time, international 
normalised ratio, albumin, ferritin, transferrin saturation, 
 on M
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Table 1 Health conditions investigated in the ALL- STAR study
Auditory- hearing Gastrointestinal Infections Neurological Pulmonary
Cholesteatoma Bowel perforation Bronchial/lung infection C/R Autonomic dysfunction Asthma
Hearing loss Coeliac disease Endocarditis Cavernoma COPD
Tinnitus Constipation Gastrointestinal infection Cerebellar dysfunction Epistaxis, C/R
Vertigo Dysphagia Genitourinary infection Cerebral necrosis Obstructive sleep apnoea
  Enterocolitis Hepatitis B, chronic Cerebrovascular accident Obstructive ventilatory 
defect
Cardiovascular Oesophageal varices Hepatitis C, chronic Cerebrovascular disease Pleural space disorders
Aortic root aneurysm Oesophagitis HIV infection Cranial nerve disorder Pneumonitis
Arteriovenous malformation Faecal incontinence Lymphatic infection Dysarthria Pulmonary diffusion defect
Atrioventricular heart block Gastritis/duodenitis Meningoencephalitis Generalised muscle weakness Pulmonary embolism
Bradycardia, sinus GORD Osteomyelitis Headaches, C/R Respiratory tract 
haemorrhage
Cardiopulm. fitness, reduced Gastrointestinal fistulas Otitis media, C/R Hydrocephalus Restrictive ventilatory defect
Conduction abnormalities Gastrointestinal haemorrhage Pelvic inflammatory disease Hydrosyringomyelia Tracheal aspiration
Congestive heart failure Gastrointestinal necrosis Pharyngitis/tonsillitis, C/R Intracranial haemorrhage Tracheal stenosis
Coronary artery disease Gastrointestinal obstruction Sinusitis, C/R Movement disorders   
Cor pulmonale Gastrointestinal strictures Soft tissue infection Multiple sclerosis Psychiatric
Dysrhythmia Gastrointestinal ulcer   Narcolepsy Anxiety
Heart valve disorder Gastroparesis syndrome Musculoskeletal Nerve root disorder Depression
High total cholesterol Malabsorption syndrome Amputation Neurogenic bladder Other psychiatric disorders
Hypertension Pancreatic insufficiency Arthralgia Neurogenic bowel   
Hypertriglyceridaemia Pancreatitis Arthritis Neuromuscular disorders Renal/urinary
LV systolic dysfunction Proctitis Bone mineral density deficit Paralytic disorder Acute kidney injury
Pericarditis   Hernia Peripheral motor neuropathy Chronic haematuria
Prolonged (QTc) interval Hepatobiliary Intervertebral disc disorder Peripheral sensory neuropathy Chronic kidney disease
Pulmonary hypertension Cholecystitis/cholelithiasis Kyphosis Pseudomeningocele Incontinence
Raynaud phenomenon Fibrosis/cirrhosis Limb length discrepancy Pseudotumour cerebri Obstructive uropathy
RV systolic dysfunction Hepatic failure Osteonecrosis Seizures Urinary bladder dysfunction
Tachycardia, sinus Hepatopathy Palatal defects, acquired   Urinary tract calculi
Thromboembolic event Portal hypertension Scoliosis Ocular/visual Vesicoureteral reflux, 
acquired
Vascular disease Veno- occlusive disease Skeletal spine disorder Cataract   
    Slipped capital femoral epiphysis Diplopia Reproductive/genital
Endocrine Haematological   Dry eye syndrome Abnormal sperm 
concentration
Abnormal glucose metabolism Anaemia Oral/dental Eyelid function disorder Cervical dysplasia
Adrenal insufficiency Coagulopathy Dental caries Glaucoma Dysfunctional uterine 
bleeding
Adult GH deficiency Iron overload Dental erosion Ocular disease, non- infectious Endometriosis
Childhood GH deficiency Neutropaenia Gingivitis Ocular surface disease Erectile dysfunction
Diabetes insipidus Polycythaemia Periodontitis Photophobia Genitourinary adhesions
GH excess Thrombocytopenia Sialadenitis, acute Phthisis bulbi Hypogonadism, central
Hyperparathyroidism Thrombocytosis Sialadenitis, chronic Retinal detachment Leydig cell insufficiency
Hyperprolactinaemia   Salivary gland dysfunction Retinopathy Polycystic ovarian syndrome
Hyperthyroidism Immunological TMJ disorder Strabismus Precocious puberty
Hypoparathyroidism Autoimmune disorders Dental maldevelopment Visual acuity, reduced (OD) Primary ovarian failure
Hypothyroidism Graft- versus- host disease   Visual acuity, reduced (OS) Prostatic hypertrophy, 
benign
Overweight/obesity Immunodeficiency Neoplasms Visual field deficit Vaginal fistula
Sarcopenic obesity   Benign neoplasms   Vaginal stenosis
SIADH   Malignant neoplasms     
Underweight         
ALL- STAR, Acute Lymphoblastic Leukemia Survivor Toxicity And Rehabilitation; COPD, chronic obstructive pulmonary disease; CR, chronic/recurrent; GH, growth hormone; GORD, gastro- oesophageal 
reflux disease; LV, left ventricle; OD, right eye; OS, left eye; QTc, corrected QT interval; RV, right ventricle; SIADH, syndrome of inappropriate antidiuretic hormone secretion; TMJ, temporomandibular joint.
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alfa-1 antitrypsin, platelets and immunoglobulins. Serum 
is stored for evaluation of viral antibodies (hepatitis A, B 
and C, cytomegalovirus and Epstein- Barr virus) in case of 
elevated transaminases. Hepatic ultrasound is performed 
using a convex, abdominal probe (C1-5, GE Logiq E9 
or E10, GE Healthcare, Chicago, USA). The liver, gall-
bladder, gall ducts, liver artery and spleen are evaluated 
for appearance and size. Portal vein flow is measured 
using Doppler ultrasound. Ultrasound 2D shear wave 
elastography is performed on the right liver lobe for eval-
uation of parenchymal stiffness and fibrosis.49
Evaluation of pancreatic function
Endpoints include pancreatic disease, endocrine and 
exocrine function, and morphological appearance. Ques-
tionnaire items include pancreatic symptoms and disease, 
diet and alcohol consumption. Fasting blood samples 
include pancreatic amylase, lipase, glucose, glycosylated 
haemoglobin, insulin and proinsulin c- peptide. Faecal 
elastase-1 is evaluated in survivors only and associated 
with occurrence of asparaginase- associated pancreatitis 
during ALL therapy. Pancreatic ultrasound is performed 
using a convex, abdominal probe (C1-5, GE Logiq E9 or 
E10, GE Healthcare,Chicago, USA) for anterior–poste-
rior measurement of caput and corpus, and for evalua-
tion of morphological changes (tumour, inflammation, 
oedema, pseudocysts and ductal ectasia).
Evaluation of bone mineral density
Endpoints include bone mineral density (BMD), bone 
fractures and biomarkers of bone metabolism. Ques-
tionnaire items include bone symptoms and joint symp-
toms, history of fractures and low BMD, age of menarche, 
hormone supplements, calcium and vitamin D intake, and 
family history of bone disease. Biomarkers include ionised 
calcium, phosphate, alkaline phosphatase, parathyroid 
hormone and 25- OH vitamin D. Bone mineral content, 
bone area, and BMD is determined by DXA of total body, 
and lumbar spine (L1–L4) and dual- femur scans. Adult 
bone mineral values are analysed as age- specific and sex- 
specific SD and expressed as z- scores and T- scores. Paedi-
atric bone mineral values are analysed as age- specific and 
sex- specific SD and expressed as z- scores. All paediatric 
bone mineral values are corrected for height.
Evaluation of cardiovascular function
Endpoints include left and right ventricular systolic and 
diastolic dysfunction, ventricular volumes and left ventric-
ular mass, myocardial fibrosis, myocardial iron deposits, 
atrial thrombosis, conduction abnormalities and hyper-
tension. Questionnaire items include cardiovascular 
symptoms, diagnoses, prescription medicine and familial 
disposition to cardiovascular disease. Automated oscil-
lometric blood pressure is measured in all, and manual 
auscultatory systolic blood pressure is measured in chil-
dren (<18 years). Cardiac biomarkers include N- ter-
minal pro b- type natriuretic peptide and troponin- T. 
Cardiac electrical activity is assessed with a 12- lead ECG. 
Imaging includes speckle tracking echocardiography and 
cardiac MRI. Echocardiography is performed using a 
Vivid E95 ultrasound scanner (GE Vingmed Ultrasound 
AS, Horten, Norway) to obtain measurements of left 
ventricular output and volumes, as well as global longi-
tudinal systolic strain. An intravenous contrast agent 
(SonoVue) is used to improve imaging.50 Cardiac MRI is 
performed using a whole body 1.5T scanner for assess-
ment of left ventricular systolic function, volumes, and 
Figure 1 ALL- STAR study overview. *Estimated survivors from 475 patients and overall survival rate of 90%. **Estimated 
number of participants based on minimum recruitment rate of 60%.ALL- STAR, Acute Lymphoblastic Leukemia Survivor Toxicity 
And Rehabilitation; NOPHO, Nordic Society of Paediatric Haematology and Oncology.
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mass. Multiparametric characterisation, including T1, 
T2, T2* and mapping is performed for visualisation of 
possible myocardial oedema and fibrosis, and to evaluate 
myocardial iron content.51 52 Intravenous gadolinium- 
containing contrast (0.15 mmol/kg Gadovist) is used for 
assessment of extracellular volume fraction in survivors 
(not controls).
Evaluation of pulmonary function
Endpoints include function of conductive and acinar 
airways, resistance of airways, alveolar volumes, alveolar 
membrane diffusion, lung clearance index, capillary 
volume, total diffusion capacity, spirometric volumes, and 
flows and reversibility. Questionnaire items include respi-
ratory symptoms, pulmonary diagnoses, smoking and use 
of prescription medicine. Prebronchodilator and post-
bronchodilator spirometry is performed using a Jaeger 
MasterScreen Bodybox and Jaeger Vyntus Spiro (Care-
Fusion, Hochberg; Vyaire Medical, Bayern) for measure-
ment of forced expiratory volume during the first second, 
forced vital capacity (FVC), and forced expiratory flow 
between 25% and 75% of FVC. Impulse oscillometry, 
including reversibility test, is performed at University 
Hospital of Aarhus using a Jaeger MasterSceen Bodybox 
and Jaeger Vyntus IOS system (CareFusion, Hochberg; 
Vyaire Medical, Bayern) to evaluate lung volumes, resis-
tance and elasticity of the lung. Nitrogen multiple breath 
washout is performed using an Exhalyzer D, N2 and SF6 
option (Eco Medics AG, Dürnten, Switzerland) to assess 
Lung Clearance Index, including indexes of acinar and 
conductive airways ventilation heterogeneity. Single 
breath diffusion capacity for carbon monoxide and 
nitrogen oxide, corrected for haemoglobin, is performed 
using a Jaeger Vyntus Body (CareFusion, Hochberg) for 
real- time single breath diffusion to evaluate diffusion 
membrane capacity and pulmonary capillary volume. 
All pulmonary measures are compared with normative 
data53–58 and with data from the matched controls.
Evaluation of peripheral and autonomic neuropathy
Endpoints include sensory nerve, motor nerve and auto-
nomic nerve dysfunction. Peripheral neuropathy is assessed 
according to recommendations from the American Academy 
of Neurology, the American Association of Electrodiagnostic 
Medicine and the American Academy of Physical Medicine 
and Rehabilitation,59 and using the Total Neuropathy Score, 
which includes self- report of sensory, motor and autonomic 
symptoms, pin sensibility, vibration sensibility (quantitative 
threshold using Vibrameter type IV (Somedic Electronics, 
Solna, Sweden) and Biothesiometer model PVD- LP (Bio- 
Medical Instruments, Ohio, USA), muscle strength (Medical 
Research Council grade 5 score), deep tendon reflexes, and 
amplitude of sural and peroneal nerves.60 Abnormal values 
corresponding to quantitative vibration threshold are calcu-
lated as percentages relative to the upper limit of normal 
values based on data from matched ALL- STAR controls 
and previously published normative data.61–63 Electroneu-
rography is performed using standard surface recording 
techniques (Neuroline 715, Ambu). A G3 Keypoint plat-
form (Dantec, Natus, USA) is used for amplification, filtra-
tion and storing of signals (motor: 2 Hz to 10 kHz; sensory: 
20 Hz to 10kHz). Electroneurography includes unilateral 
evaluation of sensory nerve action potential from the sural 
nerve, compound motor action potential from the pero-
neal nerve, the distal motor latency in the peroneal nerve 
and both sensory and motor nerve conduction velocities. 
Recorded values are compared with ALL- STAR control 
values and with unpublished national (Danish age- specific 
and gender- specific reference values), and reported as SD 
from the expected mean (z- scores). Autonomic neuropathy 
is evaluated with the validated 31- item composite autonomic 
symptom questionnaire, COMPASS 31,64 65 which assesses 
orthostatic intolerance, vasomotor, secretomotor, gastro-
intestinal, bladder and pupillomotor function. Objective 
evaluation of autonomic dysfunction is performed by anal-
ysis of heart rate variability (HRV) obtained from a 21 min 
Holter recording (13 min reclined resting period followed 
by shift to standing position with continued ECG recording 
for 8 min). The RR- interval data set derived from the ECG 
segments is analysed for heart rate and HRV. Analysis of 
HRV is performed in both the time and frequency domain 
and changes elicited by the standing position is calculated.
Evaluation of physical performance
Endpoints include cardiorespiratory fitness, level of phys-
ical activity, physical function and muscle strength. Ques-
tionnaire items include levels of sedentary behaviour 
and of physical activity, which is objectified with a 7- day 
continuous accelerometer measurement (ActiGraph 
model GT3X+, ActiGraph, Pensacola, Florida, USA). 
Cardiorespiratory fitness is evaluated using an electron-
ically braked cycle ergometer (Lode Corival Pediatric 
or Monark Ergomedic 839 E) following a modified 
Godfrey protocol.66 67 Ventilation and gas exchange 
data are determined breath- by- breath (INNOCOR ergo- 
spirometry- system, INNO00010, Innovision, DK-5260 
Odense, Denmark or Jaeger Master Screen Vyntus CPX 
and JLAB software package). Peak oxygen uptake (VO2 
peak) is defined as the highest mean over 60 s. Results 
are reported as SD from the expected mean (z- scores), 
derived from the age- matched and sex- matched ALL- 
STAR controls. Muscle strength is evaluated as isometric 
muscle strength (knee extensor, upper body (Gym 2000) 
with a strain gauge (US2A100 kg, Hottinger, Germany) 
and custom- made amplifier), and hand grip strength 
(Saehan hand dynamometer, Glanford Electronics, 
Scunthorpe). Dynamic muscle strength is evaluated by 
the counter movement jump test (FP4, HUR Labs Oy, 
Tampere, Finland) and physical functional tests (sit- to- 
stand 30 s and 60 s68 and timed up and go).69
Evaluation of kidney function
Endpoints include kidney function and kidney size. Ques-
tionnaire items include urinary tract symptoms and disease, 
and use of prescription medicine. Fasting blood samples, 
include creatinine, urea, cystatin C, sodium, potassium, 
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phosphate, albumin, ionised calcium and parathyroid 
hormone. Estimated glomerular filtration rate is evaluated 
using creatinine in adults,70 and using creatinine, urea and 
cystatin in children.71 Proteinuria is determined by the 
albumin−creatinine ratio in a morning urine specimen. A 
spot urine dip stick test is performed to evaluate haematuria 
and urine pH. Kidney size is evaluated by ultrasonography 
using a convex abdominal probe (C1-5, GE Logiq E9 or E10, 
GE Healthcare,Chicago, USA) as longitudinal anterior−
posterior length, width and cross- sectional anterior−poste-
rior length, and abnormal appearance (eg, hydronephrosis, 
cysts or tumours) is registered. Kidney size is related to body 
weight, height and lean mass.
Evaluation of pubertal status and gonadal function
Pubertal stage is evaluated in all participants aged >8 years 
at time of evaluation. Endpoints include age at menarche/
spermarche, pubertal stage and levels of reproductive 
hormones. Questionnaire items include age at menarche 
and use of contraception for females, age at spermarche 
for males and hormonal substitution. Pubertal stage is eval-
uated according to Tanner72 in combination with testic-
ular volume for males, estimated by comparative palpation 
using a Prader orchidometer.73 Results are compared with 
Danish puberty normograms.74 75 Measurements of serum 
follicle stimulating hormone, luteinising hormone, estra-
diol, testosterone, insulin- like peptide 3, inhibin B, anti- 
Müllerian hormone and sex hormone binding globulin are 
performed, and levels are compared with sex- matched and 
age- matched national reference material as well as with ALL- 
STAR controls.
Evaluation of fertility
Fertility is evaluated in all participants aged ≥18 years. 
Endpoints include impaired fertility (defined as previ-
ously diagnosed impaired fertility or infertility and/or use 
of assisted reproductive technology), number and health 
of offspring. Questionnaire data include items regarding 
health behaviour, previous relationship/marital status, 
attempts to conceive, menopause, results from fertility 
investigations, natural conceptions, use of assisted repro-
ductive technology, pregnancies, miscarriages, volun-
tary terminations, stillbirths, live births and health of 
offspring. Reproductive hormones and testicular volume 
are assessed as described in the previous section.
Evaluation of oral health and salivary secretion
Oral health assessments are performed at the Copenhagen 
University Hospital. Endpoints include oral symptoms, 
impaired oral and dental health (mucosal changes, caries, 
erosions, gingivitis, periodontitis, malocclusions, temporo-
mandibular dysfunction and salivary gland dysfunction) 
and changes in salivary microbiome and proteome. Ques-
tionnaire items include oral symptoms, current medication, 
dietary supplements, tobacco and alcohol consumption and 
oral hygiene habits. Xerostomia is assessed by means of the 
bother index,76 xerostomia inventory-877 and visual analogue 
scale (0–10).78 Additional evaluation of oral health includes a 
clinical examination with palpation of the temporomandib-
ular joint, salivary glands and regional lymph nodes; assess-
ments of the morphological and functional occlusion, dental 
status (decayed missing filled teeth scores, dental erosion 
scores, dental malformations and delayed eruptions), peri-
odontal status (gingival inflammation and dental plaque 
indices and assessment of periodontal probing depth) and 
mucosal status (mucosal changes and signs of dryness using 
clinical oral dryness score).79 Unstimulated and chewing- 
stimulated whole saliva flow rates are measured according 
to the drooling method.80 DNA is extracted from the saliva 
samples and the microbiome characterised by Human Oral 
Microbe Identification (using next- generation sequencing) 
with bacterial species- level identification based on 16S rDNA 
comparisons. Salivary proteome analyses are performed 
by means of 2D electrophoresis (2DE) and matrix- assisted 
laser desorption/ionisation time- of- flight mass spectrometry. 
Western blot analysis and ELISA are used for validation of the 
2DE results.
Evaluation of other somatic health conditions
Iron overload is evaluated with plasma levels of ferritin 
and transferrin saturation and with cardiac MRI T2* 
mapping. Hyperthroidism and hypothyroidism is inves-
tigated with questionnaire data and measurement of 
thyroid stimulating hormone and free thyroxine. Hyper-
parathyroidism is evaluated with parathyroid hormone 
and total and ionised calcium. Additional health condi-
tions specified in table 1, but not described above, are 
evaluated using questionnaire data and medical chart 
validation as reported in online supplemental table 1.
Evaluation of mental health and quality of life
Endpoints include psychiatric disease, social relations, 
emotional distress (anxiety, depression and fatigue), 
executive function and health- related quality of life. 
Questionnaire items include psychiatric diagnoses and 
psychopharmaceuticals. Additional psychosocial data are 
collected via instruments from Paediatric Quality of Life 
Inventory, Patient Reported Outcomes Measurement 
Information System, and the Behavior Rating Inventory 
of executive Function system. Specific instruments and 
versions are provided in online supplemental table 4.
Use of previously collected data for risk factor analysis
ALL patient characteristics (date of diagnosis, tumour 
burden, immunophenotype, cytogenetics, minimal residual 
disease levels, final risk stratification, participation in protocol 
randomisations and occurrence of 19 well- defined acute 
toxicities) are obtained from the NOPHO ALL2008 registry.38 
Medical chart data are used for validation of registered acute 
toxicities and for validation of self- reported health condi-
tions (including dates). Genotyping for genome wide asso-
ciation studies has been performed previously on germline 
DNA from samples obtained after clinical remission using 
the exome- enriched Illumina Infinium Omni2.5Exome-8 
BeadChip arrays and is available for approximately 70% of 
the survivor population. Whole blood samples are collected 
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from participants (including controls) not previously geno-
typed and samples are analysed using the same platform.
Data management
Study data were collected and managed using Research Elec-
tronic Data Capture (REDCap) tools hosted at Copenhagen 
University Hospital.81 82 REDCap is a secure, web- based soft-
ware platform designed to support data capture for research 
studies, providing: (1) an intuitive interface for validated data 
capture; (2) audit trails for tracking data manipulation and 
export procedures; (3) automated export procedures for 
seamless data downloads to common statistical packages; and 
(4) procedures for data integration and interoperability with 
external sources.
Statistical considerations
Cumulative incidence of the 197 health- conditions is 
calculated (individually and grouped according to organ 
system and severity grade) for survivors and controls and 
presented with 95% confidence intervals (CI). Gray’s test 
is used for comparison between the two groups. Cumu-
lative burden of the 197 health conditions is calculated 
(individually and grouped according to organ system and 
severity grades) in survivors and controls by the method 
of mean cumulative count, estimating the mean number 
of recurring or multiple health events in the presence of 
competing risk,83 and presented with 95% CIs. For this 
purpose, health conditions are categorised pre- analysis 
into three subtypes (chronic, non- recurrent; single, 
recurrent; and chronic, recurrent) based on clinical 
definitions of recurrence and chronicity, as described by 
others.40 Based on a projected sample size of 250 survi-
vors and 250 controls (survival rate of 90% in the Danish 
NOPHO ALL2008 patient cohort and a conservative 
recruitment rate of 60%), a 16% prevalence of chronic 
disease among Danish children,84 and significance level 
alpha=0.05, we will have a power of 87% to detect a HR 
of 2.0 in a Cox regression model, which is the lowest 
HR previously reported in a study comparing leukaemia 
survivors with sibling controls.85 Secondary outcomes (ie, 
description of organ- specific functions) are compared 
between survivors and controls using relevant regression 
models (eg, linear regression models, logistic regression 
models or Cox regression models). For survivors, associ-
ations of primary and secondary outcomes with therapy 
exposure and occurrence of acute toxicities are explored 
using multiple regression models. Association with single 
nucleotide polymorphisms (SNPs) is explored with 
genome- wide association analysis and using a candidate 
gene approach where relevant SNPs have been identified. 
Differences in demographics between survivor partic-
ipants and non- participants are explored using Fisher’s 
exact test for binary data and Student’s/Welch’s t- test or 
Wilcoxon rank- sum test.
Patient and public involvement
In preparation of this study, we performed a qualita-
tive interview study among adolescent and young adult 
NOPHO ALL2008 survivors to identify the challenges 
they perceive as most important.18 Results from this study 
have been incorporated into the ALL- STAR examination 
programme, securing focus on the issues most important 
to the survivors.
Longitudinal follow-up
The cohort is invited for follow- up examinations corre-
sponding to 5- year intervals from diagnosis, thereby 
aligning survival time at data capture. Results from the 
initial cross- sectional studies will inform which examina-
tions to prioritise and additional endpoints can be added 
to address new hypotheses. The ALL- STAR database 
will facilitate repeated invitations and longitudinal data 
capture. Participants will provide new informed consent 
before repeated examinations.
ETHICS AND DISSEMINATION
The study has been approved by the Regional Ethics 
Committee for the Capital Region in Denmark (no. 
H-18035090 and H-20006359), the Danish Data Protec-
tion Agency (no. VD-2018–519) and is conducted in 
accordance with the Helsinki Declaration. Written 
informed consent is obtained from all participants prior 
to enrolment. All participants can choose to participate 
in only parts of the study, can choose not to be informed 
of results, and can withdraw consent at any time. Study 
results will be published in international peer- reviewed 
scientific journals and presented at relevant conferences.
DISCUSSION
The ALL- STAR cohort is the first Nordic, population- 
based childhood and young adult ALL survivor cohort 
treated according to the same ALL protocol, to be 
uniformly evaluated for treatment- related morbidity 
across several organ systems, using both self- report data 
and objective, clinical investigations.
The evolution of long- term, adverse consequences of 
antileukaemic therapy is complex and dependent not 
only on therapy exposure and genetic susceptibility, but 
also on age at diagnosis, pre- existing morbidity, indi-
vidual resources, resources among family and peers, and 
on surrounding healthcare structures and societal struc-
tures. The comparison of a Nordic survivor cohort with 
survivor cohorts from other Western countries will provide 
insight into the consequences of differing systems, as 
well as differences in treatment regimens used. Scandi-
navian countries, and particularly Denmark, have access 
to extensive register data including health information 
and socioeconomic information, linked to the individual 
person and surrounding network through personal iden-
tification numbers.39 Coupling of systematic survivor data 
obtained in the ALL- STAR study to national register data 
will enable contextualising association studies novel to 
survivorship research.
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Strengths of the ALL- STAR study include a population- 
based design, a homogenous and well characterised 
cohort, the combination of both subjective and objec-
tive assessments of outcome, and inclusion of matched 
controls. The ALL- STAR cohort has already been char-
acterised by prospective registration of tumour burden, 
immunophenotype, cytogenetics, treatment response 
and occurrence of 19 severe toxicities, performed by 
treating physicians from time of diagnosis until end of 
therapy.38 These data enable high precision evaluation 
of risk factors and confounders associated with our main 
outcome of interest. Similarly, high quality survivor data 
is secured through self- report data, medical chart vali-
dation and systematic clinical examinations across most 
organ systems and using both well- established and novel, 
advanced techniques. This combination of data enables 
inclusion of survivor perspective while minimising risk of 
recall bias and inaccurate information. Furthermore, the 
systematic screening of organ functions facilitates capture 
of low- grade conditions, which are likely to be underes-
timated if using retrospective or self- report data only.40 
Since the investigated health conditions are not pathog-
nomic, the inclusion of matched controls, often missing 
in survivorship studies, will support conclusions made 
regarding the risk patterns, which we seek to identify.
Despite vast amounts of late effects research being 
performed, no international consensus on how to char-
acterise therapy- related late effects currently exists . 
Lack of precise definitions and uniform grading result 
in substantial variability across studies, hindering mean-
ingful pooling and comparisons of results.86 Cancer and 
therapy- related acute toxicities are traditionally defined 
and graded according to the CTCAE system and system-
atic modifications proposed by St Jude researchers has 
improved its utility for also addressing the long- term 
effects among childhood cancer survivors.43 We have 
aligned our outcome definitions accordingly and by intro-
ducing 10 additional health conditions of relevance for 
cancer survivorship research, we wish to further increase 
the relevance of this classification system.
The magnitude of late effects is often described with 
cumulative incidence; however, we encourage the use of 
the cumulative burden, which includes recurrent events 
as opposed to only first events, thereby reflecting the 
burden more comprehensively. This is illustrated by a 
study investigating therapy- related cardiovascular condi-
tions among survivors of childhood and young adult 
Hodgkin’s lymphoma. By the age of 50 years, cumulative 
incidence of all- grade cardiovascular health conditions 
did not differ between survivors and controls, while the 
cumulative burden of the same conditions was almost 
double in survivors compared with controls.40 Since none 
of the measures, however, reflect survivor perspective, 
we have included the perceived impact of the individual 
health conditions, psychosocial function and health- 
related quality of life as reported by the participants. 
Coupling of objective findings with subjective survivor 
experiences is essential for interpretation of results and 
for guiding healthcare workers and researchers when 
choosing which survivorship issues to prioritise.
There are several limitations to our study. A survival 
time of 3.5–14 years at evaluation means that the full spec-
trum of therapy- related conditions will not be captured. 
Establishment of the ALL- STAR cohort within the first 
decade of survival, however, forms the platform for longi-
tudinal follow- up, which is within the overall scope of the 
project. Interpretation of initial data will be challenged 
by a heterogeneous distribution in both age and survival 
time, but this will be adjusted for in the statistical analysis. 
Several of the health conditions evaluated in the ALL- 
STAR study rely on questionnaire data and subsequent 
medical chart validation. Low- grade conditions, which 
are not screened for are, therefore, likely to be missed. 
Finally, the ALL- STAR study outcomes are not exhaustive 
in describing the treatment- related burden. Important 
outcomes, such as semen quality, ovarian reserve and 
neurocognitive function were omitted to ensure feasi-
bility of the initial ALL- STAR initiative. Future studies of 
these important outcomes in the ALL- STAR cohort will 
benefit from the infrastructure already created.
In conclusion, the ALL- STAR study is establishing a 
Nordic childhood and young adult ALL survivor cohort 
to be systematically assessed for the cumulative incidence 
and burden of treatment- related morbidity. Results will 
supplement existing evidence regarding risk of treatment- 
related morbidity and the underlying possible biological, 
physical and psychosocial mechanisms, while providing 
novel insight into differences in survivorship related to 
specific therapy regimens, health cultures and healthcare 
systems. Findings may guide future toxicity risk grouping 
and preventive interventions during treatment and 
follow- up, ultimately ameliorating the burden of therapy 
without compromising chance of cure.
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